A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

John W. Kitchens, Nawal Kassem, William Wood, Thomas W. Stone, Rick Isernhagen, Edward Wood, Brad A. Hancock, Milan Radovich, Josh Waymire, Lang Li, Bryan Schneider

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.

Original languageEnglish
Pages (from-to)1987-1993
Number of pages7
JournalClinical Ophthalmology
Volume7
DOIs
StatePublished - Oct 9 2013

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Optical Coherence Tomography
Single Nucleotide Polymorphism
Complement Factor H
Therapeutics
Visual Acuity
Genotype
Pharmacogenomic Testing
Saliva
Genes
Injections
DNA

Keywords

  • Age related macular degeneration
  • ARMS2
  • Bevacizumab
  • Complement factor H (CFH)
  • LOC387715
  • Ranibizumab
  • Single nucleotide polymorphisms
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. / Kitchens, John W.; Kassem, Nawal; Wood, William; Stone, Thomas W.; Isernhagen, Rick; Wood, Edward; Hancock, Brad A.; Radovich, Milan; Waymire, Josh; Li, Lang; Schneider, Bryan.

In: Clinical Ophthalmology, Vol. 7, 09.10.2013, p. 1987-1993.

Research output: Contribution to journalArticle

Kitchens, John W. ; Kassem, Nawal ; Wood, William ; Stone, Thomas W. ; Isernhagen, Rick ; Wood, Edward ; Hancock, Brad A. ; Radovich, Milan ; Waymire, Josh ; Li, Lang ; Schneider, Bryan. / A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. In: Clinical Ophthalmology. 2013 ; Vol. 7. pp. 1987-1993.
@article{cf9966299e06427f8ebe9915b4c4c4b5,
title = "A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration",
abstract = "Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with {"}wet{"} AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97{\%} of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.",
keywords = "Age related macular degeneration, ARMS2, Bevacizumab, Complement factor H (CFH), LOC387715, Ranibizumab, Single nucleotide polymorphisms, Vascular endothelial growth factor",
author = "Kitchens, {John W.} and Nawal Kassem and William Wood and Stone, {Thomas W.} and Rick Isernhagen and Edward Wood and Hancock, {Brad A.} and Milan Radovich and Josh Waymire and Lang Li and Bryan Schneider",
year = "2013",
month = "10",
day = "9",
doi = "10.2147/OPTH.S39635",
language = "English",
volume = "7",
pages = "1987--1993",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

AU - Kitchens, John W.

AU - Kassem, Nawal

AU - Wood, William

AU - Stone, Thomas W.

AU - Isernhagen, Rick

AU - Wood, Edward

AU - Hancock, Brad A.

AU - Radovich, Milan

AU - Waymire, Josh

AU - Li, Lang

AU - Schneider, Bryan

PY - 2013/10/9

Y1 - 2013/10/9

N2 - Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.

AB - Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.

KW - Age related macular degeneration

KW - ARMS2

KW - Bevacizumab

KW - Complement factor H (CFH)

KW - LOC387715

KW - Ranibizumab

KW - Single nucleotide polymorphisms

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84885448955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885448955&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S39635

DO - 10.2147/OPTH.S39635

M3 - Article

VL - 7

SP - 1987

EP - 1993

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -